In Brief: Optune Pax — A Portable Device for Pancreatic Cancer

Optune Pax (Novocure), a portable device that delivers low-intensity alternating electrical fields to the abdomen, has been approved by the FDA for use with gemcitabine and nab-paclitaxel (GnP) for treatment of locally advanced pancreatic cancer in adults. It is the first device to be approved in the US for treatment of pancreatic cancer. Similar devices are available for treatment of certain lung cancers (Optune Lua) and glioblastoma (Optune Gio).